Navigation Links
Misonix Receives First Award for Forensic Equipment in China
Date:7/21/2009

FARMINGDALE, N.Y., July 21 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced receipt of its first award for forensic equipment in China from the Company's distributor CSI Technology/CStrace International. This equipment will be supplied to Chinese Law Enforcement in a major city in China. This award came from a competitive bid which focused on quality and performance. The Company expects to deliver the order in our second fiscal quarter 2010.

Michael A. McManus, Jr., President and CEO stated, "We are pleased with the first award for our Forensic products in China. The fact that the Chinese are looking for a value proposition that includes both competitive pricing and high quality suggests the manner in which the market assesses our products. We hope to win more bids as we increase our penetration into the Chinese market."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
2. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
3. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
4. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
5. Misonix Announces Participation in Annual Diabetic Foot Global Conference
6. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
7. Misonix Announces New HIFU Distribution Agreement For Portugal
8. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
9. Misonix Announces New Distribution Agreement for Portugal
10. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
11. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and ... nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... to provide first-quality education and high-level training standards to an international multidisciplinary group ... eating disorder problems. As a way to further its mission at the grassroots ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... latest in 3-D scanning device which is capable of taking digital impressions of teeth ... dentistry, such as CAD CAM restorations , in terms of speed, efficiency and ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected ... 100 organizations honored for their accomplishments in the field of midmarket financial software. , ... and recognition, and innovation. Selection is not based on revenue and those firms chosen ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... -- Transparency Market Research has released a new market ... Alcohol and Others) Market - Global Industry Analysis, Size, Share, Growth, ... benzaldehyde derivative market was valued at US$ 1.37 Bn in ... expanding at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are ...
(Date:1/17/2017)... BUDAPEST, Hungary , Jan. 17, 2017 /PRNewswire/ ... Plc. today announced positive results from Venus II, the second ... and safety of ulipristal acetate in women with abnormal bleeding ... ulipristal acetate is planned for the second half of 2017. ... Venus II supporting the efficacy and safety profile of ulipristal ...
Breaking Medicine Technology: